Emerging Targets in Antibacterial and Antifungal Chemotherapy, Softcover reprint of the original 1st ed. 1992

Emerging Targets in Antibacterial and Antifungal Chemotherapy offers constructive ideas to researchers that could lead to the discovery of entirely new classes of drugs. The authors emphasize new topics rather than review work on known antibacterials and antifungals, and identify new targets--either the rate-limiting component of a biochemical pathway or a component of the pathway that is susceptible to a ``screening'' or ``rational drug design'' approach. Each chapter reviews the biochemical pathway and its place in the cellular scheme in order to place the target in perspective. The authors, a mixture of academic researchers and drug-discovery investigators in pharmaceutical companies, also extend these theoretical concerns into practical applications and suggest useful screening methodologies. The importance of this subject area is demonstrated by the increasing number of papers in the literature that point to potential targets and screening methodologies for new antibacterials. This book also deals with antifungals, investigating the inherent limitations in existing antifungals (many of which are extremely toxic or have only limited efficacy), and pointing to major developments in the discovery of novel antifungals. Emerging Targets in Antibacterial and Antifungal Chemotherapy will be of interest to professional microbiologists, biochemists, and cell biologists in both academic and industrial laboratories.

Contributors; Preface; Part I: Antibacterial chemotherapy: Historical perspectives of approaches to antibiotics discovery-- Akira Imada and Kunimoto Hotta; Bacterial pathogens for the 90's: a case for new drug development-- George L. Drusano; DNA synthesis-- Charles S. McHenry; RNA synthesis in bacteria: mechanism and regulation of discrete biochemical events at initiation and termination-- Asis Das, Joseph DeVito, Jason Sparkowski and Frederick Warren; Bacterial cell division-- Joe Lutkenhaus; Fatty acid biosynthesis-- Suzanne Jackowski; Protein secretion in bacteria: a chemotherapeutic target?-- Rajeev Misra and Thomas J. Silhavy; Cytosolic enzymes in peptidoglycan biosynthesis as potential antibacterial targets-- W. Stephen Faraci; Strategies in Beta-lactam design-- Frank Neuhaus and Nafsika H. Georgopapadakou; Lipid A biosynthesis-- Jack Coleman; Compromising the protective barrier of the Gram-negative bacterial cell surface-- Catherine P. Reese and Joanna Clancy; Bacterial virulence factors as targets for chemotherapy-- Sarah H. Highlander and George M. Weinstock; Part II: Antifungal chemotherapy: Invasive fungal infections: problems and challenges for developing new antifungal compounds-- Thomas J. Walsh; Topoisomerase II inhibitors: prospects for new antifungal agents-- D. E. Jackson, D. P. Figgitt and S. P. Denyer; Functions for sterols in yeast membranes-- Leo W. Parks, R. Todd Lorenz and Warren M. Casey; Biochemical aspects of ergosterol biosynthesis inhibition-- Keith Barrett-Bee and Neil Ryder; Rationally designed inhibitors of sterol biosynthesis-- A. C. Oehlschlager and E. Czyzewska; Chitin synthase as a chemotherapeutic target-- Nafsika H. Georgopapadakou; Glucan biosynthesis in fungi and its inhibition-- Jan S. Tkacz; Virulence-associated mannoproteins in Candida albicans-- Richard A. Calderone and Makiko Fukayama; Screening for antifungal activity-- John F. Ryley and KeithJ. Barrett-Bee; Chemotherapeutic targets in Pneumocystis carinii-- Gregg Y. Lipschik and Joseph A. Kovacs; Index.

This is a book which will be invaluable to a variety of physicians and basic scientists working in the field of antimicrobial chemotherapy. - R C Moellering, Physician-in-Chief, Harvard Medical School, This is a book which will be invaluable to a variety of physicians and basic scientists working in the field of antimicrobial chemotherapy. - R C Moellering, Physician-in-Chief, Harvard Medical School, This is a book which will be invaluable to a variety of physicians and basic scientists working in the field of antimicrobial chemotherapy. - R C Moellering, Physician-in-Chief, Harvard Medical School